Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study.

Fabrizio VernieriNicoletta BrunelliRoberta MessinaCarmelina Maria CostaBruno ColomboPaola TorelliSimone QuintanaSabina CevoliValentina FavoniFlorindo d'OnofrioGabriella EgeoRenata RaoMassimo FilippiPiero BarbantiClaudia Altamura

Published in: The journal of headache and pain (2021)

Migraine frequency and disability gradually increased after mAbs anti-CGRP interruption. Most patients did not relapse to MO or CM despite the increase in MMDs. Our data suggest to reconsider mAbs anti-CGRP discontinuation.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
multiple sclerosis
cross sectional
peritoneal dialysis
big data
machine learning
patient reported outcomes
electronic health record
cancer therapy
deep learning
artificial intelligence
data analysis